Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

DSpace/Manakin Repository

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

Citable link to this page

 

 
Title: Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
Author: Uy, Geoffrey L.; Duncavage, Eric J.; Chang, Gue Su; Jacoby, Meagan A.; Miller, Christopher A.; Shao, Jin; Heath, Sharon; Elliott, Kevin; Reinick, Teresa; Fulton, Robert S.; Fronick, Catrina C.; O’Laughlin, Michelle; Ganel, Liron; Abboud, Camille N.; Cashen, Amanda F.; DiPersio, John F.; Wilson, Richard K; Link, Daniel C.; Welch, John S.; Ley, Timothy J.; Graubert, Timothy A.; Westervelt, Peter; Walter, Matthew J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Uy, G. L., E. J. Duncavage, G. S. Chang, M. A. Jacoby, C. A. Miller, J. Shao, S. Heath, et al. 2016. “Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy.” Leukemia 31 (4): 872-881. doi:10.1038/leu.2016.282. http://dx.doi.org/10.1038/leu.2016.282.
Full Text & Related Files:
Abstract: Traditional response criteria in MDS and AML are based on bone marrow morphology and may not accurately reflect clonal tumor burden in patients treated with non-cytotoxic chemotherapy. We used next-generation sequencing of serial bone marrow samples to monitor MDS and AML tumor burden during treatment with epigenetic therapy (decitabine and panobinostat). Serial bone marrow samples (and skin as a source of normal DNA) from 25 MDS and AML patients were sequenced (exome or 285 gene panel). We observed that responders, including those in complete remission (CR), can have persistent measurable tumor burden (i.e., mutations) for at least one year without disease progression. Using an ultra-sensitive sequencing approach, we detected extremely rare mutations (equivalent to 1 heterozygous mutant cell in 2000 non-mutant cells) months to years prior to their expansion at disease relapse. While patients can live with persistent clonal hematopoiesis in a CR or stable disease, ultimately we find evidence that expansion of a rare subclone occurs at relapse or progression. Here we demonstrate that sequencing of serial samples provides an alternative measure of tumor burden in MDS or AML patients and augments traditional response criteria that rely on bone marrow blast percentage.
Published Version: doi:10.1038/leu.2016.282
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382101/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630449
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters